Immunological Disorders & Immunotherapy
ISSN: 2593-8509
OPEN ACCESS Freely available online
Perspective

Adoptive Cell Therapy in Autoimmune Diseases: Balancing Efficacy and Safety

Karan Menon*

Department of Immunology, University of Cambridge, Cambridge, United Kingdom

DESCRIPTION

Adoptive Cell Therapy (ACT) has emerged as a potential frontier in the treatment of autoimmune diseases, offering a targeted approach to modulate the immune system and restore immune tolerance. Unlike traditional therapies that broadly suppress immune function, ACT involves reprogramming or infusing specific immune cells to selectively target autoreactive cells while preserving overall immune function. This study discusses about the principles, current applications, efficacy, safety considerations, and future prospects of adoptive cell therapy in autoimmune diseases.

Function of autoimmune diseases

Autoimmune diseases occur when the immune system erroneously attacks the body's own tissues and organs, leading to chronic inflammation, tissue damage, and organ dysfunction. Examples including rheumatoid arthritis, multiple sclerosis, lupus, and type 1 diabetes. Conventional treatments often involve non-specific immunosuppressive medications, which may cause notable side effects and may not adequately control disease progression in all patients.

Principles of adoptive cell therapy

Adoptive cell therapy aims to restore immune balance by targeting and eliminating autoreactive immune cells or by promoting regulatory immune responses. The therapy typically involves cell selection and modification identifying and isolating specific immune cells (such as T cells) that recognize autoantigens. *Ex vivo* expansion amplifying the selected cells in a laboratory setting to achieve therapeutic doses. Reinfusion administering the modified or expanded cells back into the patient to target and suppress autoreactive immune responses.

Current approaches and clinical applications

Regulatory T cell (Treg) therapy tregs play a important role in maintaining immune tolerance. ACT involving Tregs aims to bolster their suppressive function, dampening autoimmune responses. Antigen-specific T cell therapy redirecting or modifying T cells to target specific autoantigens implicated in autoimmune diseases. This approach enhances specificity and reduces off-target effects. Chimeric Antigen Receptor (CAR) T cells originally developed for cancer immunotherapy, CAR T cells are being investigate for their potential in autoimmune diseases by targeting specific cell types or cytokines involved in pathogenic immune responses.

Efficacy and safety considerations

Clinical outcomes studies have shown potential results in certain autoimmune diseases, with improvements in disease activity, reduced inflammation, and even disease remission in some cases. However, response rates can vary, and long-term durability of responses remains a challenge. Safety profiles balancing efficacy with safety is critical in adoptive cell therapy. Potential risks include cytokine release syndrome, off-target effects leading to unintended immune suppression or activation, and complications associated with immunosuppressive preconditioning regimens. Personalized approaches advancements in omics technologies enable personalized cell therapies customized to individual patient profiles, optimizing treatment efficacy and safety. Combination therapies integrating ACT with other immunomodulatory strategies or small molecule inhibitors to enhance therapeutic outcomes and minimize adverse events.

Causes

Adoptive Cell Therapy (ACT) has various causes or reasons behind its development and implementation in medical treatments. Here are some key causes:

Need for targeted therapies: Traditional treatments for diseases like cancer and autoimmune disorders often involve broad-spectrum approaches such as chemotherapy or immunosuppressive drugs. These treatments can cause considerable side effects and might not effectively target specific diseased cells or processes. ACT offers a more targeted approach by using engineered or modified cells to specifically recognize and attack diseased cells while minimizing damage to healthy tissues.

Correspondence to: Karan Menon, Department of Immunology, University of Cambridge, Cambridge, United Kingdom, E-mail: menonkaran@lt.uk

Received: 27-May-2024, Manuscript No. IDIT-24-32757; **Editor assigned:** 31-May-2024, PreQC No. IDIT-24-32757 (PQ); **Reviewed:** 14-Jun-2024, QC No. IDIT-24-32757; **Revised:** 21-Jun-2024, Manuscript No. IDIT-24-32757 (R); **Published:** 28-Jun-2024, DOI: 10.35248/2593-8509.24.9.176

Citation: Menon K (2024) Adoptive Cell Therapy in Autoimmune Diseases: Balancing Efficacy and Safety. Immunol Disord Immunother. 9:176.

Advances in cell biology and immunology: The rapid advancements in cell biology, immunology, and genetic engineering have enabled the development of ACT. Techniques such as gene editing, *ex vivo* cell expansion, and the understanding of immune cell behavior have made it possible to manipulate and enhance immune cells for therapeutic purposes.

Treatment resistance: Some diseases, such as certain types of cancer and autoimmune disorders, can become resistant to standard treatments over time. ACT provides an alternative strategy to overcome resistance by boosting the body's immune response or directly targeting resistant cells with engineered immune cells. Overall, the causes of adoptive cell therapy are rooted in the need for more effective, targeted, and personalized treatments that harness the power of the immune system to combat diseases more effectively while minimizing side effects. Adoptive cell therapy holds significant potential in revolutionizing the treatment landscape for autoimmune diseases by offering targeted immunomodulation and immune tolerance induction. While challenges such as optimizing efficacy, ensuring long-term safety, and addressing scalability research and clinical trials persist in making progress the field. Future innovations in cell engineering, patient selection, and treatment protocols will likely shape the next generation of adoptive cell therapies, ultimately improving outcomes and quality of life for patients with autoimmune diseases.